Navigation Links
Lotus Pharmaceuticals, Inc. Appoints OTC Division Head
Date:12/10/2009

BEIJING, Dec. 10 /PRNewswire-Asia/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China ("PRC"), today reported that effective December 1, 2009, Liang Fang, a controlled operating entity of Lotus, appointed Mr. Jinzhong HAN to be General Manager of the Company's Over-the-Counter Drug division ("OTC Division").

Mr. Han has over 20 years of medical sales experiences. Prior to joining Liang Fang, Mr. Han was General Manager of the OTC Division of Tianjin Taiping Pharmaceutical Company for two years. Prior to such time, he served approximately seven years as Vice General Manager and Chief of Marketing Officer of Beijing Yongkang Pharmaceutical Company. Mr. Han has a bachelor degree of business management from Air Force Institute of Logistics.

"Mr. Han has strong management skills in medical sales and marketing and logistics, proven with his previous tenure in both state-owned enterprises and private entities," said Dr. Zhong Yi Liu, Chairman and Chief Executive Officer of the Company. "We are bringing a strong leader to our OTC Division to further grow the OTC Division and lead a team of approximately 40 employees, of which approximately half of such employees are medical sales professionals. We are confident that Mr. Han's expertise in the area will assist the expansion of our OTC business into 2012, as well as efficiency in delivery of services to drug stores in Beijing."

About Lotus Pharmaceuticals, Inc. (http://www.lotuspharma.com )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Lt
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy
2. Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
3. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
4. Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijings Prestigious ChangAn Avenue
5. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
6. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
7. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
9. Trubion Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
10. EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
11. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... Society for Reproductive Medicine (ASRM), a leading professional organization ... In his new role as treasurer, Dr. Hill ... will have a voice in furthering the mission of ... since 1984 when he joined while conducting fellowship training ...
(Date:12/24/2014)... December 23, 2014 PharmaBoardroom,s ... out today and available for free download , digs ... change and growth in the sector today. One ... successes has been in developing a homegrown pharmaceutical manufacturing base, ... production still remains some way off. A cursory comparison with ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... DUBLIN, October 28 , ... EU to Treat,hyperphosphataemia >1.78mmol/L in Chronic Kidney Disease Patients ... (LSE: SHP, NASDAQ: SHPGY ), the global specialty,biopharmaceutical ... Mutual Recognition Procedure for an extension to the current,indication ...
... ... An incident of terrorism, accident, or improper disposal of radioactive ... catastrophe would impact the population with increased cancer and associated illnesses ... distribution network. In response to this threat, Technical Associates created the ...
... Oct. 27 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... authorization in the European Union for rilonacept, an ... Syndromes (CAPS) with severe symptoms, including Familial Cold ... adults and children aged 12 years and older. ...
Cached Biology Technology:Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease 2Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease 3Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease 4Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law 2Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law 3Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law 4Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) 2Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) 3Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) 4Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) 5Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) 6
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... 2013Universit Laval researchers have developed a highly effective method for ... low-emissions fuel for vehicles. The team led by Professor Frdric-Georges ... issue of the Journal of the American Chemical Society ... convert methanol into carbon dioxide in a single step using ...
... of genetically modified mice that Western University scientists call ... run far but they aren,t smart, is furthering the ... Marco Prado and his team at Robarts Research Institute ... of this neurotransmitter becomes available in the brain. ...
... 2013 Based on its recent analysis of the ... with the 2013 European Frost & Sullivan Award for ... originally used for medical point-of-care testing to create an ... test requires only a single-step DNA collection procedure from ...
Cached Biology News:Too green to be true? Researchers develop highly effective method for converting CO2 into methanol 2'Forrest Gump' mice show too much of a good thing, can be bad 2Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market 2Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market 3Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market 4
Rabbit polyclonal to ZA20D3 ( Abpromise for all tested applications). entrezGeneID: 54469 SwissProtID: Q6FIF0...
... Super-Dark, Super-Small! Capture high-resolution chemiluminescent ... Imaging System. High-sensitivity camera is cooled ... and wide dynamic range for high ... time. The light-tight cabinet provides optimum ...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Biology Products: